Get started

COCP

COCP and playing the setupBuy Shares Strategy - Buy COCP @ $0.44 RISK 4.7% -> Stop Loss $0.4193 TARGET 1 Reward: +4.7% $0.4607 TARGET 2 Reward: +11.4% $0.4900 Looking to break out of this nice wedge; RSI is looking good, STOCHASTIC is trending neutral however. 8 EMA about to cross the 34 EMA, hoping to catch the move before liftoff, with preplanned risk (stop loss) in effect. Volume is lacking, needs more volume for the push. *Let's see what happens* DISCLAIMER - I am not a professional trader. These are merely my thoughts and possible moves; i enjoy watching these stocks validate my process or slap me across the face lol. If you are in need of professional assistance with your trades, don't look here. I am not that guy.
NASDAQ:COCPLong
by mrmaximo74
1
$COCP Short Articles Published Drowned out by FACTS PPS Rises03-06-2020, 3.5 Million Share Institutional Buy-In tells only a snippet of the overall story with this dream stock. sec.report To get the real grasp of what we have here, look to my previous post and take in this analogy as deeply as possible: In the Coronavirus Market: $COCP is to Treatment what $IBIO is to Vaccines or what $OPK is to Testing. $COCP has completed all the financing and funding needed with two public offerings recently and are now aggressively pursing the development of Novel Anitiviral Compounds for treatment of any Corona infections including COVID-19 They have exclusive patent rights to the treatment and are in the process of advancing it quickly through a preclinical trial program. Shorts will continue to write articles to downplay these facts as much as possible because the stock has a HUGE short position
NASDAQ:COCPLong
by StockGuild
$COCP Clears the Runway for a $10+ move In the coming daysBOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage Biotechnology company discovering and developing novel antiviral therapeutics, today announced it has initiated its Coronavirus program. finance.yahoo.com “Following our acquisition of patent rights and know-how from KSURF and our recently completed financing, we are aggressively pursuing the development of novel antiviral compounds for the treatment of Coronavirus infections using our established proprietary drug discovery platform. Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development. We will seek opportunities for collaborations as we advance our programs,” stated Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. Cocrystal recently entered into a license agreement with KSURF to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development. For additional information about the Company’s development pipeline, please visit www.cocrystalpharma.com. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com. COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development. “We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, President of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.” Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution providing the Company with the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C, influenza and norovirus.
NASDAQ:COCPLong
by StockGuild